NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.20 +0.82 (+1.05%) GOLD FUTURES
2,317.00 -7.20 (-0.31%) DOW
39,089.45 +205.19 (+0.53%) Bitcoin GBP
49,853.49 -656.19 (-1.30%)
Revolution Medicines, Inc. (RVMD)
| Previous close | 38.88 |
| Open | 38.07 |
| Bid | 38.23 x 200 |
| Ask | 38.37 x 200 |
| Day's range | 38.04 - 38.96 |
| 52-week range | 15.44 - 40.21 |
| Volume | |
| Avg. volume | 1,494,724 |
| Market cap | 6.527B |
| Beta (5Y monthly) | 1.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.86 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.58 |
GuruFocus.comInsider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)
On May 3, 2024, Jack Anders, the Chief Financial Officer of Revolution Medicines Inc (NASDAQ:RVMD), sold 10,000 shares of the company.
GlobeNewswireRevolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the qua
- GlobeNewswire
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San DiegoREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research p
